![[Feedback]](/icons/banner/feedbackACT.gif){kind=icon}
![[For Subscribers]](/icons/banner/subscriberACT.gif){kind=icon}
![[Archive]](/icons/banner/archiveACT.gif){kind=icon}
![[Search]](/icons/banner/searchACT.gif){kind=icon}
![[Contents]](/icons/banner/tocACT.gif){kind=icon}
|
|
|
|
|
||
E Chu, JC Drake, DM Koeller, S Zinn, CA Jamis-Dow, GC Yeh and CJ Allegra
Medicine Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892.
A series of Adriamycin-resistant human breast MCF-7 and human colon DLD- 1 cancer cell lines were established by stepwise selection. The concentration of Adriamycin required to inhibit cell proliferation by 50% (IC50) in the parent breast line (MCF-7), Adriamycin-resistant lines (MCF-Ad5 and MCF-Ad10), and a 5-fluorouracil (5-FU)-revertant line (MCF-R) was 0.005, 3.3, 6, and 4.9 microM, respectively. The Adriamycin IC50 value for the resistant colon line (DLD-Ad) was 8.2 microM, 68-fold higher than that for its parent line (DLD-1) (IC50 = 0.12 microM). The MCF-Ad5 and MCF-Ad10 cells were cross-resistant to 5- FU, with respective 5-FU IC50 values of 11.7 and 22.5 microM, or 7.3- and 14-fold less sensitive than their parent MCF-7 (IC50 = 1.6 microM) line. The MCF-R line completely reverted in sensitivity to 5-FU, with an IC50 of 1.7 microM. The resistant DLD-Ad line was 3.5-fold more resistant to 5-FU than was the parent DLD-1 line. Using both the 5- fluoro-2'-deoxyuridine-5'-monophosphate binding and catalytic assays for measurement of thymidylate synthase (TS) activity, there was significantly increased TS activity in the resistant MCF-Ad5 (2.4- and 2.5-fold), MCF-Ad10 (11.5- and 6.8-fold), and DLD-Ad (4.8- and 10.7- fold) lines, for binding and catalytic assays, respectively, compared with their parent MCF-7 and DLD-1 lines. The level of TS in cytosolic extracts, as determined by Western immunoblot analysis, was markedly increased for the resistant MCF-Ad5 (31-fold), MCF-Ad10 (46-fold), and DLD-Ad (52-fold) cells. Measurement of TS mRNA levels by Northern analysis revealed elevation of TS mRNA in the resistant MCF-AD5 (16.7- fold), MCF-Ad10 (31-fold), and DLD-Ad (55-fold) cells. Southern analysis showed that this increase in TS mRNA was not accompanied by any major rearrangements or amplification of the TS gene. Incorporation of 5-FU into the RNA and DNA of the resistant MCF-Ad10 cells was not significantly different, compared with that for parent MCF-7 cells. These studies suggest that exposure of human breast and human colon cancer cells to Adriamycin leads to overexpression of TS, with concomitant development of resistance to 5-FU.
This article has been cited by other articles:
|
|
 |
|
  C. Aschele, D. Debernardis, R. Bandelloni, S. Cascinu, V. Catalano, P. Giordani, S. Barni, D. Turci, G. Drudi, S. Lonardi, et al. Thymidylate synthase protein expression in colorectal cancer metastases predicts for clinical outcome to leucovorin-modulated bolus or infusional 5-fluorouracil but not methotrexate-modulated bolus 5-fluorouracil Ann. Onc., December 1, 2002; 13(12): 1882 - 1892. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Aschele, D. Debernardis, G. Tunesi, F. Maley, and A. Sobrero Thymidylate Synthase Protein Expression in Primary Colorectal Cancer Compared with the Corresponding Distant Metastases and Relationship with the Clinical Response to 5-Fluorouracil Clin. Cancer Res., December 1, 2000; 6(12): 4797 - 4802. [Abstract] [Full Text]
|
|
|
|
|
|
M. Nishiyama, W. Yamamoto, J.-S. Park, R. Okamoto, H. Hanaoka, H. Takano, N. Saito, M. Matsukawa, T. Shirasaka, and M. Kurihara Low-Dose Cisplatin and 5-Fluorouracil in Combination CanRepress Increased Gene Expression of Cellular Resistance Determinants to Themselves Clin. Cancer Res., September 1, 1999; 5(9): 2620 - 2628. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Aschele, D. Debernardis, S. Casazza, G. Antonelli, G. Tunesi, C. Baldo, R. Lionetto, F. Maley, and A. Sobrero Immunohistochemical Quantitation of Thymidylate Synthase Expression in Colorectal Cancer Metastases Predicts for Clinical Outcome to Fluorouracil-Based Chemotherapy J. Clin. Oncol., June 1, 1999; 17(6): 1760 - 1760. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Ju, J. Pedersen-Lane, F. Maley, and E. Chu Regulation of p53 expression by thymidylate synthase PNAS, March 30, 1999; 96(7): 3769 - 3774. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. M. Davies, P. G. Johnston, S. Kaur, and T. G. Allen-Mersh Colorectal Liver Metastasis Thymidylate Synthase Staining Correlates with Response to Hepatic Arterial Floxuridine Clin. Cancer Res., February 1, 1999; 5(2): 325 - 328. [Abstract] [Full Text] [PDF]
|
|
 |
 |
 |
|
 |
 |
 |
